Wire · operational-macro
Fierce Pharma Asia—Roche's $1.2B obesity deal; Asahi Kasei's FDA nod; Verastem's KRAS boon
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 October 2026 · Fusion42 review
Roche secured a $1.2 billion deal with China's Rona Therapeutics to enter the obesity drug market targeting ALK7. Asahi Kasei gained FDA approval for a novel herpes drug, and Verastem showed promising early clinical results for a KRAS G12D inhibitor in pancreatic cancer.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 13 Oct 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
You have a clear opening to enter China’s obesity and cancer treatment markets as Roche and Verastem move aggressively in ALK7 and KRAS therapies. Your next partnership or product development should focus on these high-potential areas where funding and regulatory approval have recently accelerated.
◆ Coverage
4 sources · first reported 13 Oct 2026 · latest 16 Oct 2026
◆ Related on Wire
◆ Topics